75 results on '"Di Raimondo, Francesco"'
Search Results
2. AIPSS‐MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib
3. A case of high‐risk AML in a patient with advanced systemic mastocytosis
4. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia
5. Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
6. Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant
7. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
8. Pegylated Asparaginase‐Induced Liver Injury: A Case‐Based Review and Data From Pharmacovigilance
9. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
10. The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large b‐cell lymphoma
11. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
12. Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials
13. Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol
14. Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study
15. Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases
16. The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET‐2‐adapted HD0607 trial
17. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data
18. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase III study
19. Serum free light chains and multiple myeloma: Is it time to extend their application?
20. The multi‐tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real‐world data
21. Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real‐world study
22. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
23. A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
24. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
25. Immune off‐target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma
26. Predictive value of the CLL‐IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment
27. Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases
28. Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib
29. NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types
30. Lenalidomide and low‐dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials
31. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line
32. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients
33. Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome
34. Role of Nuclear Heme Oxygenase‐1 in Bortezomib Induced Cell Death
35. Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study
36. Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study
37. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O‐CLL1‐GISL study
38. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients
39. BCR‐ABL residues interacting with Ponatinib are critical to preserve the tumorigenic potential of the oncoprotein (59.6)
40. High-throughput sequencing for the identification ofNOTCH1mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications
41. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients
42. A snapshot of asparaginase-induced liver insufficiency
43. BCR‐ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein
44. Total body computed tomography scan in the initial work‐up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O‐CLL1‐GISL study
45. External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia
46. Chromosome 2p gain in monoclonal B‐cell lymphocytosis and in early stage chronic lymphocytic leukemia
47. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles
48. Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients
49. Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies
50. Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.